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Nebulization therapy is an approach for the treatment of respiratory diseases such as asthma which was not 
anticipated in the international recommendations for the treatment of asthma and which merits study. Even if the 
place of nebulizers in the treatment of asthma exacerbations has been validated, this is not the case for adult 
asthmatic subjects with chronic asthma. While asthma control for most patients can be achieved using metered-dose 
inhaler and dry powder inhaler therapy, some patients may require regular home nebulized therapy. 
Before determining the objectives and therapeutic characteristics of nebulization in the treatment of chronic 
asthma in the adult patient, we shall first describe the pathophysiological elements involved in the treatment of 
asthma and of the couple ‘nebulized substance-nebulizer’ leading to an optimal nebulization. 
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Introduction 
Nebulization therapy is an approach for the treatment of 
respiratory disease which has been in use for over 4000 yr 
since the Indians inhaled leaves of the Atvopa belladona 
plant in order to relieve coughing. Galenic aerosols are 
widely used in the treatment of asthma today, for treatment 
of both asthma exacerbations and chronic asthma. Their 
relative lack of systemic side-effects together with very 
satisfactory therapeutic effects makes them preferable to 
orally administered galenic forms. 
Near the dawn of the 21 st century, there are a number of 
different methods of inhalation including metered-dose 
inhalers, (MDIs, with or without inhalation chambers and 
automatic release systems), dry powder inhalers (DPIs) and 
nebulizers (compressor-jet or ultrasonic systems). While the 
place for MDIs and DPIs in the therapeutic arsenal for 
asthma has begun to be acknowledged (1) and is the 
preferred mode of therapy, the place of nebulizers is less 
clear cut and remains the subject of controversy both from 
the point of view of indication and from the type of 
medication to use. Beyond the optimal treatment of the 
asthmatic patient, important economic (cost-benefit con- 
siderations) and environmental (such as the use of chloro- 
fluorocarbons in the propellant gas of certain aerosols, 
which have been shown to damage the ozone layer) inter- 
ests also come into play. In this regard, the National 
Association for Medical Direction of Respiratory Care has 
recently convened a consensus conference and published 
guidelines (2). 
Before determining the objectives and therapeutic char- 
acteristics of nebulization in the treatment of chronic 
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asthma in the adult patient, we shall first describe the 
pathophysiological elements involved in the treatment of 
asthma and of the couple ‘nebulized substance-nebulizer’ 
leading to an optimal nebulization. 
Pathophysiological Basis of the 
Treatment of Asthma 
Asthma is characterized clinically by variable wheezy dys- 
pnoea which is often nocturnal and subsides spontaneously 
or following treatment. To this old clinical definition, 
a more recent anatomophysiological definition has been 
suggested. 
Asthma is a chronic inflammatory disorder of the air- 
ways in which many cells play a role, including mast cells 
and eosinophils. In susceptible individuals this inflam- 
mation causes symptoms which are usually associated 
with widespread but variable airway obstruction that is 
often reversible either spontaneously or with treatment, 
and causes an associated increase in airway responsive- 
ness to a variety of stimuli (1). 
Thus, the best definition of asthma includes bronchospasm, 
inflammation and bronchial hyperreactivity. Any treatment 
must take into account at least one and preferably all of 
these pathophysiological components. 
The successful treatment of an asthmatic patient also 
requires the definition and treatment of the factors which 
give rise to or aggravate his or her asthma. This allows one 
not only to prevent and treat asthma exacerbations but also 
to’ control the asthmatic patient better. There are many 
such factors which require careful investigation and these 
include allergens, viruses, sinus infections and sociopsycho- 
logical factors. Rhinitis and sinusitis would appear to be a 
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potential therapeutic target for nebulization treatment. 
They are frequently associated with asthma and their 
treatment could modify the course of chronic asthma. 
Nebulizers and Parameters Leading to 
Optimal Nebulization 
An aerosol is defined as a suspension or a solution of a 
liquid or solid in the form of fine particles dispersed in a 
gas. The physicochemical properties of an aerosol govern 
the deposition of the particles in the airways and therefore 
their action. Nebulizers also fall under this rule and must 
conform with a ‘list of characteristics’ in common with all 
inhalation systems. The particles must have a median mass 
diameter (MMD) in the region of 1-5,~~rn and a geometric 
standard deviation (GSD) as close to 1 pm as possible. The 
size of emitted particles does not always correspond to the 
size of inhaled particles: hypertonic particles capture water 
and increase in diameter while hypotonic particles dry out 
in the presence of air and thus decrease in diameter. 
Two types of nebulizers with different characteristics are 
available: ultrasonic nebulizers and compressor-jet nebuliz- 
ers. Compressor-jet nebulizers are reliable and powerful 
but are expensive and noisy. Ultrasonic nebulizers are 
silent, powerful and reliable but expensive. In addition to 
the heterogeneity which exists for each type of nebulizer the 
‘global’ performance of each type of nebulizer is different. 
Unlike ultrasonic nebulizers, compressor-jet nebulizers 
often produce a greater polydispersion (with a GSD often 
greater than 5pm) and a longer nebulization period and 
necessitate (taking into account the existence of a residual 
volume) the dilution of substances in saline. The apparatus 
must also respond to several essential criteria. Suspensions 
(colimycin, DNase, budesonide) unlike solutions (such as 
terbutaline, salbutamol, ipratropium bromide or sodium 
cromoglycate) can only be administered by compressor-jet 
nebulizers. Nebulization periods should never last more 
than 10 min if one hopes to achieve a satisfactory level of 
compliance. Finally, regular and careful maintenance of the 
nebulizer is essential in order to avoid contamination by 
pathogenic organisms such as Klebsiella, Servatia or Entero- 
batter (3) which if allowed to proliferate can give rise to 
pneumonitis and sinusitis, 
Substances Which can be Used in 
Nebulizers 
The substance to be nebulized constitutes the second part of 
the nebulization couple. It must fit in with certain patho- 
physiological objectives which we have already described. 
There is great polymorphism throughout the world both in 
the legal authorization and in the practical usage of these 
substances. Bronchodilators (short-acting &agonists and 
anticholinergic agents) are on the whole not just the object 
of legal authorization but also require specific formulations 
in order to be given by nebulization. 
Other substances are often used by clinicians without 
legal authorization and sometimes in the absence of publi- 
cations validating their use. In general, these medications 
are ‘orphan medications’ and should become the subject of 
reflection and validation studies should be started. The use 
of corticosteroids is a perfect example. It is recommended 
not to include absorbable steroids such as dexamethasone, 
hydrocortisone, methylprednisolone, prednisolone and 
prednisone in aerosols (2). In certain countries, inhaled 
steroids such as budesonide are the object of legal authori- 
zation and special formulations are available for use in 
nebulizers but there are very few studies on the feasibility, 
the efficacy and the tolerance of corticotherapy given by the 
nebulizer route. 
Objectives of Nebulization Therapy 
Now that the preliminary elements have been defined, we 
can turn to the five theoretical objectives and interests 
of home-administered nebulization treatment for adult 
asthmatic subjects: (1) improve inadequate nebulization- 
respiration co-ordination; (2) increase the amount of 
bronchodilator administered to the bronchi; (3) decrease 
the need for oral corticosteroids; (4) parallel contact with 
the sinus mucosa; (5) action on mucus production. 
THEORETICAL OB]ECTIVE 1: DECREASE THE 
LACK OF NEBULIZATION-RESPIRATION 
CO-ORDINATION PRESENT IN 20-75% OF 
PATIENTS 
The lack of co-ordination between hand (administration of 
the aerosol) and lung (inhalation) can be utilized to justify 
the use of nebulization therapy. Such an attitude would 
seem unreasonable in mild or moderate asthma where many 
devices are available to minimize this problem such as the 
Autohaler@, inhalation chambers and DPIs. The therapeu- 
tic ehicacies of these systems are equal to those of nebulizers 
although they may be somewhat less rapid. In contrast, in 
seriously ill asthmatic subjects who are unable to use 
inhalation chambers, DPIs or Autohaler@, the use of 
nebulizers can be justified. 
THEORETICAL OBJECTIVE 2: INCREASE THE 
AMOUNT OF BRONCHODILATOR REACHING 
THE BRONCHI 
Whatever the system used, be it MD1 and DPI or nebulizer, 
the proportion of the preparation reaching the bronchi is of 
the order of 10% (4). When equal doses of &agonists are 
compared, the bronchodilator effects of all methods are 
comparable (4). However, nebulizers allow easy admin- 
istration of higher doses of drugs when needed for severe 
exacerbations. For instance: the nebulization of 10 mg of 
salbutamol produces a significantly greater increase in 
FEV, than 200 pg of salbutamol delivered by MD1 (5). The 
interest in the use of nebulizers is therefore in the possibility 
of administering greater amounts of the principal active 
drug thanks to differences in formulations of nebulized 
626 TOPICAL REVIEWS 
substances. When bronchodilators are considered, the for- 
mulation used in nebulizers contains 5-50 times more active 
ingredient than that used in sprays. 
Does the use of higher doses of bronchodilators result in 
better control of the asthmatic patient? When only strict 
respiratory physiological criteria are considered (and in 
particular FEV,), a dose-response effect has been shown 
for &-agonists and anticholinergic agents (6). Clinical 
studies in chronic asthmatics have, however, given rise to 
more controversial results. O’Driscoll (7) adopted a mid- 
way position which would seem to correspond more closely 
to daily practice and identified from among his severe 
asthmatic patients several who were resistant to treatment 
by bronchodilator in MD1 formulation but who showed 
improvement in 50% of cases when treated by nebulization. 
This group of patients therefore simply required higher 
doses of bronchodilators in order to be properly treated, 
but unfortunately this requirement cannot be detected 
by any currently available laboratory test. At the term of 
a 5 yr study, O’Driscoll and Bernstein (8) concluded that 
the home nebulizer is safe (no tachyphylaxis and no sur- 
mortality occurred) and induces a subjective (as assessed 
by questionnaires) and objective (post-treatment morning 
PEF rates) benefit over that period of time in a small but 
relevant number of carefully selected patients with severe 
asthma. 
An increase in the levels of bronchodilators administered 
inevitably leads to symptoms including trembling, hypo- 
kalaemia, tachycardia and cardiac problems. Care should 
thus be taken when prescribing such treatment for elderly 
patients or those who have a history of myocardial ischae- 
mia or arrhythmia. Moreover, the regular use of &agonists 
has been the subject of controversy and these drugs have 
been implicated in the increase in asthma mortality 
although Suissa et al. (9) concluded that there was no link 
between increased mortality in asthmatic and non- 
asthmatic subjects and the use of short-acting P,-agonists. 
An overconsumption of these drugs over prolonged time 
periods should certainly be an alarm signal and reflects 
both the severity and the level of activity of the disease. 
Simply to increase the dose of short-acting &-agonists in 
the face of unstable asthma is insufficient and the clinician 
should adapt the levels of anti-inflammatory drugs 
prescribed accordingly (1). 
The existence of paradoxical bronchoconstrictions fol- 
lowing the use of nebulizers containing /&-agonists has been 
reported (10). These bronchoconstrictions are not related to 
the dose of drug but have been attributed to the hypotonic 
or acid solutions or to the use of preservers (benzalkonium) 
or stabilizers and antioxidants (metabisulphites or EDTA). 
THEORETICAL OBJECTIVE 3: DECREASE THE 
NEED FOR ORAL CORTICOTHERAPY IN 
ORDER TO REDUCE SIDE-EFFECTS 
Two categories of substances are concerned: corticosteroids 
and ‘others’ (furosemide, heparin, lysine salicylic acid, 
sodium cromoglycate). However, studies performed cor- 
rectly (i.e. double-blind, placebo, cross-over studies) show- 
ing equivalent therapeutic efficacy as compared with oral 
corticotherapy and thus corticosparing effects remain to be 
published. 
THEORETICAL OBJECTIVE 4: TO REACH THE 
SINUS MUCOSA SIMULTANEOUSLY WITH THE 
BRONCHIAL MUCOSA 
When performing a medical work-up for asthma, one 
frequently finds the coexistence of a sinus disorder (acute 
sinusitis, chronic sinusitis or nasal sinusoidal polyps). This 
coexistence has led a number of authors to discuss the 
possibility of a link between sinus disorders and asthma. 
This has essentially been because of the improvement in the 
control of asthma following surgical or medical treatment 
of the sinus disorder in patients suffering from severe 
asthma (11,12). 
_ Thanks to the use of a facial mask, nebulization treat- 
ment can have an impact simultaneously on the ENT 
sphere and the bronchial sphere whereas the use of mouth- 
piece reduces the impact on the ENT sphere, although the 
penetration of the nebulized drugs into the sinus cavities 
has never been demonstrated. Corticosteroids are often of 
particular interest as similar inflammatory processes exist in 
the sinuses and bronchi of an asthmatic subject and treat- 
ment of a straightforward rhinitis by nasally administered 
corticosteroids often results in an improvement in bronchial 
hyperreactivity (13). 
THEORETICAL OBJECTIVE 5: ACTION ON THE 
MUCUS 
A general view has been that mucociliary clearance tends to 
be impaired in asthma, albeit with a great variability among 
asthmatic subjects (14). Paganin et al. (15) showed that 
irreversible abnormalities observed on CT scans of asth- 
matic subjects, such as cylindric and varicous bronchiecta- 
sis, are more extensive in severe forms of asthma. The 
clinical implications of this finding remain to be understood 
but, in patients suffering from chronic obstructive pulmon- 
ary diseases, chronic mucus hypersecretion was indepen- 
dently and significantly associated with FEV, decline and 
increased risk of subsequent hospitalization (16). More- 
over, inhalation of isotonic saline aerosol enhances muco- 
ciliary clearance in asthmatic subjects (17). Thus, it is 
possible that the subjective improvement described by some 
patients using nebulizers is due to ‘mucomodulator’ effects 
of this type of aerosol. In a retrospective study in 102 
patients, Andersson and Boethius suggested that patients 
with bronchial hypersecretion seemed to benefit more from 
the long-term home-nebulized &agonist treatment than 
patients without (18). It is clear that hypersecretion is often 
associated with endobronchial inflammation and that an 
anti-inflammatory treatment is thus necessary. However, no 
scientific literature has documented the possible beneficial 
effect of home nebulizers in chronic severe asthma with 
chronic mucus hypersecretion. 
Conclusion 
Even if the place of nebulizers in the treatment of asthma 
exacerbations has been validated (1): this is not the case for 
adult asthmatic subjects with chronic asthma. While 
asthma control for most patients can be achieved using 
MD1 and DPI therapy, some patients may require regular 
home-nebulized therapy. This form of treatment was not 
anticipated in the international recommendations for the 
treatment of asthma (1) and merits study, as recently stated 
(2). In agreement with others (2,19), we recommend that the 
following should be performed before prescribing nebulizer 
treatment for an adult with chronic asthma: (a) to ensure 
that this treatment is indicated after checking for correct 
MD1 dosage and compliance, treating all possible trigger 
factors and trying other forms of treatment and document- 
ing the need for higher doses of bronchodilators for the 
individual patient; (b) to optimize the anti-inflammatory 
treatment before beginning nebulizer use; (c) to ensure 
comprehensive and detailed instructions necessary for use 
of the apparatus (set-up, use, cleaning, regular checks); (d) 
to reflect whether the treatment is still required after 1 
month of use at home with careful checks on the peak flow 
values and taking into account the diary in which should be 
noted number of exacerbations, nocturnal symptoms, need 
for other medication. 
We would also suggest that the following situations 
would indicate the use of nebulizer therapy as a result of 
quality studies: (a) asthma with chronic sinusitis and/or 
nasosinusoidal polyps; (b) hypersecretion in asthma with or 
without bronchial dilatation; (c) severe chronic asthma 
poorly controlled by other treatments (not forgetting the 
above recommendations); (d) cortico-dependent asthma, 
with the aim of reducing the dose of corticosteroids admin- 
istered orally. In contrast, the available data would seem to 
suggest that this treatment should not be used in the 
following cases: (a) non-severe asthma with lack of hand- 
lung co-ordination; (b) the simple need for a bronchodilator 
in non-severe asthma. 
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